Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 9, 2015, Pages 1583-1588

  Li, Y ^a   Wang, Y Y ^a   Fei, H R ^a   Wang, L ^a   Yuan, C L ^a  

^a QINGDAO CENTRAL HOSPITAL   (China)

Author keywords

Immune; Primary; Rituximab; Thrombocytopenia; Thrombopoietin

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; RECOMBINANT PROTEIN; THROMBOPOIETIN;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MALE; RESPONSE TIME; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADOLESCENT; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT PROTEINS; REMISSION INDUCTION; RITUXIMAB; THROMBOPOIETIN; YOUNG ADULT;

EID: 84942255134     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. PROVAN D, STASI R, NEWLAND AC, BLANCHETTE VS, BOLTON-MAGGS P, BUSSEL JB, CHONG BH, CINES DB, GERNSHEIMER TB, GODEAU B, GRAINGER J, GREER I, HUNT BJ, IMBACH PA, LYONS G, MCMILLAN R, RODEGHIERO F, SANZ MA, TARANTINO M, WATSON S, YOUNG J, KUTER DJ. International consensus report on the investigation and management of primary imrnune thrombocytopenia. Blood 2010; 115: 168-186.
2. PORTIELJE JE, WESTENDORP RG, KLUIN-NELEMANS HC. Morbidity and mortality in adult with idiopathic thrombocytopenic purura. Blood 2001; 97: 2549- 2554.
3. GALL B, YEE A, BERRY B, BIRCHMAN D, HAYASHI A, DANSEREAU J, HART J. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 2010; 32: 1167-1171.
4. SCHWEIZER C, REU FJ, HO AD, HENSEL M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007; 86: 711-717.
5. ZECCA M, NOBILI B, RAMENGHI U, PERROTTA S, AMENDOLA G, ROSITO P, JANKOVIC M, PIERANI P, DE STEFANO P, BONORA MR, LOCATELLI F. Rituximab for the treatment of refractory autoimmune hemolyticanemia in children. Blood 2003; 101: 3857-3861.
6. STASI R, STIPA E, FORTE V, MEO P, AMADORI S. Variable pattern of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872-3873.
7. PEÑALVER FJ, JIMÉNEZ-YUSTE V, ALMAGRO M, ALVAREZLARRÁN A, RODRÍGUEZ L, CASADO M, GALLUR L, GIRALDO P, HERNÁNDEZ R, MENOR D, RODRÍGUEZ MJ, CABALLERO D, GONZÁLEZ R, MAYANS J, MILLÁN I, CABRERA JR. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006; 85: 400-406.
8. ZAJA F, BATTISTA ML, PIRROTTA MT, PALMIERI S, MONTAGNA M, VIANELLI N, MARIN L, CAVALLIN M, BOCCHIA M, DEFINA M, IPPOLITI M, FERRARA F, PATRIARCA F, AVANZINI MA, REGAZZI M, BACCARANI M, ISOLA M, SOLDANO F, FANIN R. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008; 93: 930-933.
9. GÓMEZ-ALMAGUER D, SOLANO-GENESTA M, TARÍN-ARZAGA L, HERRERA-GARZA JL, CANTÚ-RODRÍGUEZ OG, GUTIÉRREZ-AGUIRRE CH, JAIME-PÉREZ JC. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010; 116: 4783-4785.
10. CHANG M, NAKAGAWA PA, WILLIAMS SA, SCHWARTZ MR, IMFELD KL, BUZBY JS, NUGENT DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoanibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895.
11. CREMER M, SCHULZE H, LINTHORST G, FOLMAN CC, WEHNERT S, STRAUSS G, VON DEM BORNE AE, WELTE K, BALLMAIER M. Serum levels of thrombopoietin, IL- 11, and IL-6 in pediatric thrombocytopenias. Ann Hematol 1999; 78: 401-407.
12. ALEEM A, ALASKAR AS, ALGAHTANI F, RATHER M, ALMAHAYNI MH, AL-MOMEN A. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Int J Hematol 2010; 92: 283-288.
13. RODEGHIERO F, STASI R, GERNSHEIMER T, MICHEL M, PROVAN D, ARNOLD DM, BUSSEL JB, CINES DB, CHONG BH, COOPER N, GODEAU B, LECHNER K, MAZZUCCONI MG, MCMILLAN R, SANZ MA, IMBACH P, BLANCHETTE V, KÜHNE T, RUGGERI M, GEORGE JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adult and children: report from an international working group. Blood 2009; 113: 2386-2393.
14. SMITH MR. Rituximab (Monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
15. STASI R, STIPA E, FORTE V, MEO P, AMADORI S. Variable patterns of response to rituximab in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872-3873.
16. METJIAN A, ABRAMS CS. New insights and therapeutics for immune-mediated thrombocytopenia. Expert Rev Cardiovasc Ther 2008; 6: 71-84.
17. STASI R, EVANGELISTA ML, AMADORI S. Novel thrombopoietic agents: A review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-912.
18. HASAN A, MICHEL M, PATEL V, STASI R, CUNNINGHAM- RUNDLES S, LEONARD JP, BUSSEL J. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol 2009; 84: 661- 665.
19. LIU X, HONG XN, GU YJ, WANG BY, LUO ZG, CAO J. Intemtitial pneumonitis during rituxi-mab containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 1778-1783.
20. MALONEY DG, GRILLO-LÓPEZ AJ, WHITE CA, BODKIN D, SCHILDER RJ, NEIDHART JA, JANAKIRAMAN N, FOON KA, LILES TM, DALLAIRE BK, WEY K, ROYSTON I, DAVIS T, LEVY R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
21. HUANG YC, LIU CJ, LIU CY, PAI JT, HONG YC, TENG HW, HSIAO LT, CHAO TC, GAU JP, LIU JH, HSU HC, CHIOU TJ, CHEN PM, YU YB, TZENG CH. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 1145-1151.